English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 2/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ✅ Correction passed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -68.49%
Price change 2019 → 2020: 439.20%
Price change 2020 → 2021: -13.49%
Price change 2021 → 2022: -48.58%
Price change 2022 → 2023: -64.82%
Price change 2023 → 2024: 12.58%
Price change 2024 → 2025: -54.50%
Price change 2025 → 2026: 8.91%
Price change 2026 (year to date): 18.03%
Financial growth
Revenue CAGR (8 years): -9.53%
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.27
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -2.99
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 12.00% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| SpineGuard S.A. | – | 0.27 | +1.6 % | 🔒 |
| Valbiotis S.A. | – | 0.73 | +56.9 % | – |
| Implanet S.A. | – | 14.66 | +5.0 % | – |
| Novacyt S.A. | – | 0.45 | +28.1 % | – |
| Fermentalg | – | 0.20 | +38.5 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|